SML2728
ML375
≥98% (HPLC)
别名:
(S)-9b-(4-Chlorophenyl)-1-(3,4-difluorobenzoyl)-1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-one, (S)-9b-(4-Chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one, ML 375, VU0483253
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C23H15ClF2N2O2
化学文摘社编号:
分子量:
424.83
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
SMILES string
Fc1c(ccc(c1)C(=O)N2[C@]4(N(CC2)C(=O)c5c4cccc5)c3ccc(cc3)Cl)F
InChI key
GXBAKXRLQAPKEE-QHCPKHFHSA-N
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -150 to -175, c = 0.5 in chloroform-d
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
ML375 is an orally active, brain-penetrant, potent and M5 subtype-selective muscarinic acetylcholine receptor (mAChR) negative allosteric modulator (NAM) (IC50 = 300/790 nM against 10 μM NMS-induced Ca2+ mobilization in h/r M5-transfected CHO cells; h/r M1-M4 IC50 >30 μM) that reduces N-methylscopolamine (NMS) ML5 dissociation rate without competing against NMS for receptor binding. M375 shows in vivo efficacy in rat models of substances addiction (cocaine, ethanol, oxycodone) with excellent multispecies pharmacokinetic properties.
Orally active, brain-penetrant, potent & M5-selective muscarinic acetylcholine receptor (mAChR) NAM with in vivo efficacy in rat models of substances addiction.
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Alice E Berizzi et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 43(7), 1510-1517 (2018-02-28)
Despite the cost to both individual and society, alcohol use disorders (AUDs) remain a major health risk within society, and both relapse and heavy drinking are still poorly controlled with current medications. Here we demonstrate for the first time that
Barak W Gunter et al.
Addiction biology, 23(5), 1106-1116 (2017-10-19)
Cocaine use disorder (CUD) remains a debilitating health problem in the United States for which there are no Food and Drug Administration-approved treatment options. Accumulating anatomical and electrophysiological evidence indicates that the muscarinic acetylcholine receptor (mAChR) subtype 5 (M5 )
Patrick R Gentry et al.
Journal of medicinal chemistry, 56(22), 9351-9355 (2013-10-30)
A functional high throughput screen and subsequent multidimensional, iterative parallel synthesis effort identified the first muscarinic acetylcholine receptor (mAChR) negative allosteric modulator (NAM) selective for the M5 subtype. ML375 is a highly selective M5 NAM with submicromolar potency (human M5
Robert W Gould et al.
ACS chemical neuroscience, 10(8), 3740-3750 (2019-07-04)
Opioid use disorder (OUD) is a debilitating neuropsychiatric condition characterized by compulsive opioid use, dependence, and repeated relapse after periods of abstinence. Given the high risk of developing OUD following prescription opioid use, the continued need for opioid-induced analgesia, and
Alice E Berizzi et al.
Molecular pharmacology, 90(4), 427-436 (2016-07-28)
Recently, the first subtype-selective allosteric modulators of the M5 muscarinic acetylcholine receptor (mAChR) have been described, but their molecular mechanisms of action remain unknown. Using radioligand-binding and functional assays of inositol phosphate (IP) accumulation and Ca(2+) mobilization in a recombinant
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持